A Prospective, Randomized, Double-Blind, Multicenter, Phase 3 Study to Assess the Safety and Efficacy of Intravenous Ceftolozane/tazobactam Compared With Meropenem in Adult Patients with Ventilated Nosocomial Pneumonia

Trial Profile

A Prospective, Randomized, Double-Blind, Multicenter, Phase 3 Study to Assess the Safety and Efficacy of Intravenous Ceftolozane/tazobactam Compared With Meropenem in Adult Patients with Ventilated Nosocomial Pneumonia

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs Ceftolozane/tazobactam (Primary) ; Meropenem
  • Indications Bacterial infections; Nosocomial pneumonia; Pseudomonal infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ASPECT-NP
  • Sponsors Cubist Pharmaceuticals; Merck Sharp & Dohme
  • Most Recent Events

    • 11 Sep 2017 Planned End Date changed from 19 Oct 2018 to 19 Jun 2018.
    • 11 Sep 2017 Planned primary completion date changed from 29 Sep 2018 to 28 May 2018.
    • 18 Jul 2017 This trial has been completed in Portugal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top